Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Gastroenterología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 3
ClinicalTrials.gov
Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment naïve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV
INTERVENTIONAL
Inicio: 11 de jul de 2013
ID: NCT01866930
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, 12-Week (With an Extension to 52 Weeks in a Subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared to BGF Delivered by MDI HFA in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 27 de sept de 2022
ID: NCT05573464
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433
INTERVENTIONAL
Inicio: 21 de mar de 2018
ID: NCT03345823
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 31 de ene de 2022
ID: NCT04987307
Completado
ClinicalTrials.gov
Short and Long-term Outcomes After Transplantation With Hyper-reduced Liver Grafts in Low-Weight Pediatric Recipients
OBSERVATIONAL
Inicio: 21 de abr de 2018
ID: NCT03594864
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
INTERVENTIONAL
Inicio: 12 de feb de 2019
ID: NCT03797326
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
INTERVENTIONAL
Inicio: 10 de sept de 2025
ID: NCT06919965
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis
INTERVENTIONAL
Inicio: 8 de jul de 2016
ID: NCT02660359
Completado
Fase 3
ClinicalTrials.gov
Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
INTERVENTIONAL
Inicio: 4 de nov de 2014
ID: NCT02163759
Completado
ClinicalTrials.gov
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00428220
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
INTERVENTIONAL
Inicio: 28 de feb de 2020
ID: NCT04210115
Completado
ClinicalTrials.gov
Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis
OBSERVATIONAL
Inicio: 16 de nov de 2022
ID: NCT05641025
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of rhHNS (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Early Stage Mucopolysaccharidosis Type IIIA Disease
INTERVENTIONAL
Inicio: 26 de feb de 2014
ID: NCT02060526
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
INTERVENTIONAL
Inicio: 24 de may de 2024
ID: NCT06419374
Reclutando
Fase 2
ClinicalTrials.gov
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 10 de oct de 2024
ID: NCT06598943
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
INTERVENTIONAL
Inicio: 18 de jun de 2018
ID: NCT03518086
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis
INTERVENTIONAL
Inicio: 7 de nov de 2024
ID: NCT06632457
Terminado
Fase 3
ClinicalTrials.gov
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
INTERVENTIONAL
Inicio: 14 de abr de 2011
ID: NCT01285557
Terminado
Fase 2
ClinicalTrials.gov
Randomised, Double-blind, Placebo-controlled and Parallel Group Trial to Investigate the Effects of Two Doses (Up-titration to a Fixed Dose Regimen) of Oral BI 685509 on Portal Hypertension After 24 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Compensated Cirrhosis
INTERVENTIONAL
Inicio: 27 de abr de 2022
ID: NCT05161481
Desconocido
ClinicalTrials.gov
Effect of a Neuromuscular Electrostimulation Protocol on the Triceps Surae in Older Adults
INTERVENTIONAL
Inicio: 20 de jun de 2023
ID: NCT06046885
Anterior
1
...
22
23
24
...
434
Siguiente
Filtros